New drug application accepted by FDA for GSK’s momelotinib
18th August 2022 Uncategorised 0Therapy for the treatment of myelofibrosis has received significant results from phase 3 trial
More: New drug application accepted by FDA for GSK’s momelotinib
Source: News
